Snowball logo
logo
4768

Rznomics

476830 • KQ
₩22,800.00-₩700.00  (2.98%)
Estimate
Beta
-0.319
Growth
Revenue, YoY
-88.61%
Net income, YoY
92.52%
FCF, YoY
-443.44%
About the company
Ticker
476830
ISIN
Country
South Korea
Sector (GICS)
Healthcare
Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome. Rznomics Inc. was incorporated in 2017 and is headquartered in Seongnam-si, South Korea.

Frequently asked questions

What sector does Rznomics (476830) operate in?

Rznomics belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Rznomics (476830) current stock price?

As of the latest data, Rznomics stock price is ₩22,800, with a previous close of ₩23,500. Rznomics lost -₩700 in the last trading session, representing a -2.98% loss.

What is Rznomics (476830) current market capitalization?

Rznomics market cap is approximately 639.66 billion.

What is Rznomics (476830) EBITDA?

Rznomics EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -6.04 billion.

Does Rznomics (476830) pay dividends?

No. Rznomics does not pay a dividend.

What is Rznomics (476830) beta (volatility) score?

Rznomics has a beta of -0.319, indicating lower volatility than the overall market.